@article{e3b4da0fe3844db6b91fa6e3c53e2947,
title = "Assessing in-session rumination and its effects on CBT for depression",
abstract = "The study evaluated if rumination of patients during therapy (i.e., in-session rumination) relates to whether or not they do less well in CBT treatment. We developed a reliably assessed in-session rumination observational measure and evaluated its relationship to depression over the course of CBT. Rated sessions came from 63 treatment-na{\"i}ve patients with major depressive disorder who participated in CBT in the PReDICT study (Dunlop et al., 2017). In-session rumination was operationalized as repetitive, negative, and passive talking about depressive topics. Trained undergraduates rated the intensity and duration of in-session rumination occurring during 57 initial therapy sessions (i.e., session one) and 45 sessions in the middle of treatment (i.e., session eight). The observational ratings were sufficiently reliable (all ICCs > 0.69). Mixed model results indicated that greater intensity of in-session rumination during the initial treatment session predicted higher levels of subsequent clinician-rated depressive symptoms (p < .023). Regression results indicated that greater intensity and duration of in-session rumination at session 8 significantly predicted higher clinician-rated symptoms at end of treatment (p's < 0.02). In-session rumination intensity and duration were not, however, related to subsequent self-reported depressive symptoms. The results support efforts to identify which patients might benefit from rumination-specific interventions.",
keywords = "Behavioral ratings in-session rumination, In-session rumination, Rumination duration, Rumination during CBT, Rumination intensity",
author = "Kennedy, {J. C.} and Dunlop, {B. W.} and Craighead, {L. W.} and Nemeroff, {C. B.} and Mayberg, {H. S.} and Craighead, {W. E.}",
note = "Funding Information: This work was supported by the National Institute of Mental Health , Grant/Award Numbers: P50 MH077083 , R01 MH080880 , and a gift from the Fuqua family Foundations. Funding Information: The authors report the following financial disclosures: JCK has no financial disclosures. BWD: Dr. Dunlop has received research support from Acadia , Boehringer Ingelheim , Compass Pathways, Aptinyx, NIMH , Usona Institute , Sage, and Takeda, and has served as a consultant to Greenwich Biosciences, Myriad Neuroscience, Cerebral Therapeutics, Otsuka, Sage, and Sophren Therapeutics. LWC: Dr. Craighead receives royalties from New Harbinger and John Wiley. CBN: Dr. Nemeroff receives research grants from NIH . He is a consultant to: ANeuroTech (division of Anima BV), Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, Corcept Therapeutics Pharmaceuticals Company. He hold stock in the following companies: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, TRUUST Neuroimaging. He is a member of the Scientific Advisory Boards of ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, Heading Health, TRUUST Neuroimaging, and on the Board of Directors of Gratitude America, Xhale Smart, Inc. He holds the following patents: US 6,375,990B1 and US 7,148,027B2. HSM: Dr. Mayberg receives research support from NIMH and NINDS , has served as a consultant to Abbott Labs and has licensed intellectual property on DBS for Depression to Abbott Labs. WEC: Dr. Craighead receives research support from the NIH; is a board member of Hugarheill ehf, an Icelandic company dedicated to the prevention of depression; receives book royalties from John Wiley; and is supported by the Mary and John Brock Foundation, the Pitts Foundation, and the Fuqua family foundations. He is a consultant to the George West Mental Health Foundation and a member of the Scientific Advisory Boards of AIM for Mental Health and the ADAA. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
month = dec,
doi = "10.1016/j.brat.2022.104209",
language = "English",
volume = "159",
journal = "Behaviour Research and Therapy",
issn = "0005-7967",
publisher = "Elsevier Ltd.",
}